The recent successes of chimeric antigen receptor (CAR) T cell therapy in hematologic malignancies have led to tremendous interest in the immunotherapeutic field, and the potential of genetically modified T cells now expands into solid tumors and infectious diseases. However, current manufacturing processes for CAR T cells are complex and labor-intensive.
In this two-part webinar you will learn more about the new T Cell Transduction – Large Scale (TCT-LS) process for the CliniMACS Prodigy® Platform. We share process details and differentiators, along with limitations and how to choose the right process type for your requirements. Furthermore, we will walk you through recent data on TCR-modified T cell manufacturing for AML treatment, and how the overall process was shortened to only 8 days.
Join this webinar to gain insights into: